PubMed:32110025 JSONTXT

{"project":"luoyt2021_800_3","denotations":[{"id":"T1","span":{"begin":22,"end":37},"obj":"CI"},{"id":"T10","span":{"begin":1576,"end":1580},"obj":"DP"},{"id":"T11","span":{"begin":741,"end":745},"obj":"DP"},{"id":"T12","span":{"begin":600,"end":604},"obj":"DP"},{"id":"T13","span":{"begin":480,"end":484},"obj":"DP"},{"id":"T14","span":{"begin":225,"end":233},"obj":"DP"},{"id":"T15","span":{"begin":392,"end":411},"obj":"DP"},{"id":"T16","span":{"begin":1015,"end":1034},"obj":"DP"},{"id":"T17","span":{"begin":858,"end":877},"obj":"DP"},{"id":"T2","span":{"begin":1652,"end":1667},"obj":"CI"},{"id":"T20","span":{"begin":1519,"end":1523},"obj":"CI"},{"id":"T21","span":{"begin":1347,"end":1351},"obj":"CI"},{"id":"T22","span":{"begin":1265,"end":1269},"obj":"CI"},{"id":"T23","span":{"begin":1061,"end":1065},"obj":"CI"},{"id":"T24","span":{"begin":628,"end":636},"obj":"CI"},{"id":"T25","span":{"begin":1881,"end":1889},"obj":"CI"},{"id":"T26","span":{"begin":1480,"end":1488},"obj":"CI"},{"id":"T27","span":{"begin":1245,"end":1253},"obj":"CI"},{"id":"T28","span":{"begin":422,"end":430},"obj":"CI"},{"id":"T29","span":{"begin":810,"end":817},"obj":"CI"},{"id":"T3","span":{"begin":791,"end":806},"obj":"CI"},{"id":"T30","span":{"begin":690,"end":697},"obj":"CI"},{"id":"T31","span":{"begin":445,"end":452},"obj":"CI"},{"id":"T32","span":{"begin":337,"end":344},"obj":"CI"},{"id":"T4","span":{"begin":269,"end":284},"obj":"CI"},{"id":"T5","span":{"begin":128,"end":177},"obj":"DP"},{"id":"T6","span":{"begin":59,"end":108},"obj":"DP"},{"id":"T7","span":{"begin":110,"end":114},"obj":"DP"},{"id":"T8","span":{"begin":179,"end":183},"obj":"DP"},{"id":"T9","span":{"begin":1734,"end":1738},"obj":"DP"},{"id":"T33","span":{"begin":310,"end":314},"obj":"CI"}],"text":"Precision Medicine of Sodium Benzoate for the Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD).\nOBJECTIVE: Behavioral and psychological symptoms of dementia (BPSD) are associated with poorer prognosis of dementia. A 24-week study demonstrated that sodium benzoate, a D-amino acid oxidase (DAAO) inhibitor, surpassed placebo in improving cognitive function in early-phase Alzheimer's disease; however, benzoate did not excel placebo in another 6-week study on BPSD. The current study examined whether the precision medicine approach was able to identify specific individuals with BPSD who could benefit from benzoate treatment.\nMETHODS: In the randomized, double-blind, placebo-controlled, 6-week trial, 97 patients with BPSD were allocated to receive 250-1500 mg/day of sodium benzoate or placebo. Cognitive function was measured by the Alzheimer's disease assessment scale-cognitive subscale (ADAS-cog) and behavioral and psychological symptoms were mainly measured by Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD). DAAO level, amino acids (L-serine, D-serine, L-alanine, and D-alanine, glycine), and two antioxidants (catalase, superoxide dismutase) were assayed in peripheral blood.\nRESULTS: After benzoate treatment, DAAO inhibition was correlated with ADAS-cog decrease (p = 0.034), while baseline DAAO level was correlated with baseline BEHAVE-AD score. Multiple linear regression analyses showed that cognitive improvement after benzoate treatment was correlated with DAAO decrease, female gender, younger age, BMI, baseline BPSD severity, and antipsychotic use.\nCONCLUSION: The finding suggests that sodium benzoate may have potential to benefit cognitive function in a fraction of BPSD patients after 6 weeks of treatment. Of note, the precision medicine approach may be helpful for identifying individuals who could respond to benzoate. More studies are warranted to confirm the preliminary findings.\nTRIAL REGISTRATION: The trial was registered online (https://clinicaltrials.gov/ct2/show/NCT02103673)."}

{"project":"Linmchun_800_3","denotations":[{"id":"T1","span":{"begin":110,"end":114},"obj":"DP"},{"id":"T10","span":{"begin":791,"end":806},"obj":"CI"},{"id":"T11","span":{"begin":810,"end":817},"obj":"CI"},{"id":"T12","span":{"begin":22,"end":37},"obj":"CI"},{"id":"T13","span":{"begin":269,"end":284},"obj":"CI"},{"id":"T14","span":{"begin":337,"end":344},"obj":"CI"},{"id":"T15","span":{"begin":1652,"end":1667},"obj":"CI"},{"id":"T16","span":{"begin":445,"end":452},"obj":"CI"},{"id":"T17","span":{"begin":310,"end":314},"obj":"CI"},{"id":"T18","span":{"begin":392,"end":411},"obj":"DP"},{"id":"T19","span":{"begin":858,"end":877},"obj":"DP"},{"id":"T2","span":{"begin":59,"end":108},"obj":"DP"},{"id":"T20","span":{"begin":1015,"end":1034},"obj":"DP"},{"id":"T21","span":{"begin":1061,"end":1065},"obj":"CI"},{"id":"T22","span":{"begin":1265,"end":1269},"obj":"CI"},{"id":"T23","span":{"begin":1347,"end":1351},"obj":"CI"},{"id":"T24","span":{"begin":1519,"end":1523},"obj":"CI"},{"id":"T25","span":{"begin":225,"end":233},"obj":"DP"},{"id":"T26","span":{"begin":422,"end":430},"obj":"CI"},{"id":"T27","span":{"begin":628,"end":636},"obj":"CI"},{"id":"T28","span":{"begin":1245,"end":1253},"obj":"CI"},{"id":"T29","span":{"begin":1480,"end":1488},"obj":"CI"},{"id":"T3","span":{"begin":179,"end":183},"obj":"DP"},{"id":"T30","span":{"begin":1881,"end":1889},"obj":"CI"},{"id":"T4","span":{"begin":128,"end":177},"obj":"DP"},{"id":"T5","span":{"begin":480,"end":484},"obj":"DP"},{"id":"T6","span":{"begin":600,"end":604},"obj":"DP"},{"id":"T7","span":{"begin":741,"end":745},"obj":"DP"},{"id":"T8","span":{"begin":1576,"end":1580},"obj":"DP"},{"id":"T9","span":{"begin":1734,"end":1738},"obj":"DP"},{"id":"T31","span":{"begin":690,"end":697},"obj":"CI"}],"text":"Precision Medicine of Sodium Benzoate for the Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD).\nOBJECTIVE: Behavioral and psychological symptoms of dementia (BPSD) are associated with poorer prognosis of dementia. A 24-week study demonstrated that sodium benzoate, a D-amino acid oxidase (DAAO) inhibitor, surpassed placebo in improving cognitive function in early-phase Alzheimer's disease; however, benzoate did not excel placebo in another 6-week study on BPSD. The current study examined whether the precision medicine approach was able to identify specific individuals with BPSD who could benefit from benzoate treatment.\nMETHODS: In the randomized, double-blind, placebo-controlled, 6-week trial, 97 patients with BPSD were allocated to receive 250-1500 mg/day of sodium benzoate or placebo. Cognitive function was measured by the Alzheimer's disease assessment scale-cognitive subscale (ADAS-cog) and behavioral and psychological symptoms were mainly measured by Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD). DAAO level, amino acids (L-serine, D-serine, L-alanine, and D-alanine, glycine), and two antioxidants (catalase, superoxide dismutase) were assayed in peripheral blood.\nRESULTS: After benzoate treatment, DAAO inhibition was correlated with ADAS-cog decrease (p = 0.034), while baseline DAAO level was correlated with baseline BEHAVE-AD score. Multiple linear regression analyses showed that cognitive improvement after benzoate treatment was correlated with DAAO decrease, female gender, younger age, BMI, baseline BPSD severity, and antipsychotic use.\nCONCLUSION: The finding suggests that sodium benzoate may have potential to benefit cognitive function in a fraction of BPSD patients after 6 weeks of treatment. Of note, the precision medicine approach may be helpful for identifying individuals who could respond to benzoate. More studies are warranted to confirm the preliminary findings.\nTRIAL REGISTRATION: The trial was registered online (https://clinicaltrials.gov/ct2/show/NCT02103673)."}